Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
Detailed findings from a Phase III study comparing the investigational GLP-1 receptor agonist albiglutide to Lispro, were presented today at the ADA Meeting in Philadelphia, USA.
Read more -
GSK extends tender offer for all outstanding shares of Human Genome Sciences
GSK today announced it has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash to 5:00 pm New York City ti...
Read more -
GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia
GlaxoSmithKline plc (GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant; (gabapentin ena...
Read more -
GSK announces expiration of Hart-Scott-Rodino waiting period for tender offer for HGS
GSK today announced that the waiting period under the HSR Act, as amended, has expired with respect to GSK tender offer for all the outstanding shares of Human Genome Sciences.
Read more -
GSK and EPSRC announce creation of new Chair in Sustainable Chemistry at the University of Nottingham
GSK and The Engineering and Physical Sciences Research Council today announced that they will jointly contribute to the funding for a Chair in Sustainable Chemistry to be based ...
Read more -
Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade®
GSK announced today that it has submitted regulatory applications in the EU and US related to eltrombopag (Promacta®/Revolade® ) and its use to increase platelet count...
Read more -
GSK secures future of local playing fields with Fields in Trust as part of London 2012 legacy
GSK has today entered a partnership with Fields in Trust (FIT) to secure the future of its Swyncombe Avenue Playing Fields, where hundreds of local people already enjoy sport, b...
Read more -
GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma
GlaxoSmithKline plc. today announced the start of a Phase III programme evaluating the combination of dabrafenib, its BRAF inhibitor, and trametinib, its MEK inhibitor, in patie...
Read more -
GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents
GlaxoSmithKline plc (GSK) which has the marketing rights for Lovaza (omega-3-acid ethyl esters) in the US and Puerto Rico, confirmed that U.S. District Judge Sue Lewis Robinson,...
Read more -
GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue sarcomas
GSK announced that the EMA CHMP has issued a positive opinion recommending marketing authorisation for Votrient for the treatment of adult patients with selective subtypes of ad...
Read more -
Innovative public-private collaboration launches to tackle antibiotic research
GlaxoSmithKline and AstraZeneca today welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies work...
Read more -
Two overall winners announced at prestigious national award ceremony in London’s Science Museum
For the first time in its 15 year history the judges of the GlaxoSmithKline (GSK) IMPACT Awards could not choose one overall winner for the awards so instead awarded two prizes....
Read more -
GSK statement on tender offer to acquire Human Genome Sciences
GSK today commented on Human Genome Sciences Board of Directors decision to recommend against GSK's tender offer to acquire all of the outstanding shares of HGS for US$13.00 per...
Read more -
GlaxoSmithKline completes transaction to increase its ownership in Theravance
Following approval by Theravance, Inc. stockholders at their Annual Meeting held on 15 May 2012, GSKs acquisition of 10,000,000 shares of Theravance common stock has now completed.
Read more -
GlaxoSmithKline to fully acquire Cellzome for £61 million
GSK today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomic...
Read more -
GSK statement on BBC Panorama broadcast: ‘the truth about tax’
GSK issued the following statement in response to the BBC Panorama programme related to Corporation Tax payments in the UK and Luxembourg broadcast tonight, Monday 14 May 2012.
Read more -
Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.
Read more -
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash.
Read more -
GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK today announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all...
Read more -
James Shannon named GlaxoSmithKline Chief Medical Officer
James Shannon has been named GSK's Chief Medical Officer (CMO), effective 1 May. James will report to R&D Chairman Moncef Slaoui and be based in London. He will be account...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
